Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F. Graetz C, et al. Among authors: pfeuffer s. Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13. Mult Scler. 2019. PMID: 29532745
Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L. Ruck T, et al. Among authors: pfeuffer s. Neurology. 2018 Dec 11;91(24):e2233-e2237. doi: 10.1212/WNL.0000000000006648. Epub 2018 Nov 7. Neurology. 2018. PMID: 30404783 Free PMC article.
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG. Pfeuffer S, et al. J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16. J Neurol. 2019. PMID: 30446966
Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
Keller CW, Ruck T, McHugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Münz C, Nimmerjahn F, Wiendl H, Lünemann JD. Keller CW, et al. Among authors: pfeuffer s. Ann Clin Transl Neurol. 2019 Dec;6(12):2586-2594. doi: 10.1002/acn3.50935. Epub 2019 Nov 4. Ann Clin Transl Neurol. 2019. PMID: 31682087 Free PMC article.
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Rolfes L, Pfeuffer S, Ruck T, Windhagen S, Oschlies I, Pavenstädt HJ, Angenendt L, Wiendl H, Krämer J, Meuth SG. Rolfes L, et al. Among authors: pfeuffer s. Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1):e638. doi: 10.1212/NXI.0000000000000638. Print 2020 Jan. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31704887 Free PMC article. No abstract available.
54 results